American Cancer Society Joins the Worldwide Innovative Network (WIN) in Personalized Cancer Medicine Consortium - WIN Consortium
Posted: Thursday, September 19, 2024
September 19, 2024 - American Cancer Society and Worldwide Innovative Network (WIN) in personalized cancer medicine consortium join forces to advance innovative cancer research.
“By joining the global network of WIN, American Cancer Society is expecting to increase its global reach and to help improve cancer outcomes across the world,” said Dr. William L. Dahut, Chief Scientific Officer of the American Cancer Society (ACS).
“We are extremely proud to welcome the ACS to WIN,” said Dr. Wafik S. El-Deiry, Chair of WIN Consortium, Director of the Legorreta Cancer Center, Associate Dean for Oncologic Sciences at The Warren Alpert Medical School, Brown University, and ACS Research Professor “For more than 10 decades, the American Cancer Society has been dedicated to pursuing better outcomes for every cancer, every life in the USA. It’s mission has been to improve the lives of people with cancer and their families through advocacy, research, and patient support, to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer. As the WIN Consortium continues to develop and implement the next generation of Precision Oncology trials with attention to equity, working with ACS provides an exciting path to innovate and demonstrate ways for how patients with cancer will be managed in the next several decades. In this regard, the ACS is a major stakeholder and wonderful partner to work with.”
“The collaboration will look at amplifying and promoting the ACS’s and the WIN Consortium’s impact in advancing Precision Oncology to support their respective overarching missions, that include facilitating translation of discoveries in cancer prevention, therapeutics, and biomarkers as they relate to screening, prediction of or association with therapeutic benefit. This includes AI algorithm-driven therapeutic IND-studies at a growing global footprint of sites. We look forward to increasing access to innovative precision interventions in global communities through scientific approaches and patient navigation. We look forward to working collaboratively to facilitate goals of the emerging ACS-HBCU-Cancer Trials Consortium through biomarker and genomic/AI-based studies in cancer precision therapeutics. Addressing the global burden of cancer through new therapeutics targeting virally-associated cancers, precancerous conditions, rare cancers, cancers from specific tissue origins or tissue agnostic trials are other opportunities of mutual interest between ACS and WIN. We think that partnering between ACS and WIN will foster greater collaboration with academia, pharma companies and foundations in precision oncology research while enhancing networking opportunities and collaborations with ACS-funded researchers.” said Dr. William L. Dahut.
“With so many patients and families affected by cancer, waiting, and hoping for effective cures and treatments, siloed research gets in the way of innovation. WIN was the first consortium that assembled all stakeholders of cancer care, from academia, industry, and patient advocates to work together across the globe. It was also the first organization to launch a N-of-One study using transcriptomics in addition to genomics to inform therapeutic choice in the WINTHER study. WIN offers a platform to launch compelling precision oncology and early diagnosis studies internationally building upon its experience in genomics and transcriptomics. It is a great honor to welcome such a leading cancer-fighting organization in the USA as American Cancer Society” said Dr Razelle Kurzrock, Chief Medical Officer of WIN, Professor of Medicine, Associate Director Clinical Research, MCW Cancer Center and Linda T. & John A. Mellowes of Precision Oncology.
View the full article here: Download pdf
About the American Cancer Society
The American Cancer Society is a leading cancer-fighting organization with a vision to end cancer as we know it, for everyone. For more than 110 years, we have been improving the lives of people with cancer and their families as the only organization combating cancer through advocacy, research, and patient support. We are committed to ensuring everyone has an opportunity to prevent, detect, treat, and survive cancer. To learn more, visit cancer.org or call our 24/7 helpline at 1-800-227-2345. Connect with us on Facebook, X, and Instagram.
About WIN Consortium
WIN Consortium is a non-profit association headquartered in France. The WIN network assembles 37 world-class academic medical centers, industries, research organizations and patient advocates spanning 20 countries and 4 continents, aligned to launch trials to bolster Precision Oncology across the world. WIN is the organizer of the WIN symposia in Precision Oncology.
Contact
www.winconsortium.org
Catherine Bresson, Director Operational Team
catherine.bresson@winconsortium.org